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Alzheimer’s disease (AD) is a neurodegenerative disorder whose clinical onset is mainly characterized by memory loss. During
AD progression, behavioral and psychological symptoms of dementia (BPSD) frequently occur. In this paper we evaluated the
association between AD and the short/long (S/L) functional polymorphism of the promoter region of the 5-hydroxytryptamine
(5-HT) transporter gene (SLC6A4). The S-allele shows a 2-fold reduced transcriptional rate, causing an imbalance in 5-HT
intracellular availability that might in turn trigger behavioral and cognitive alterations. We also genotyped the SLC6A4 promoter
functional variant rs25531 (A → G). By comparing the genotypic and allelic frequencies in an Italian population of 235 AD and
207 controls, we found an association between 5-HTTLPR and AD (odds ratio for the L-allele versus the S-allele: 0.74, associated
P value = .03), while no diﬀerence was found for the rs25531. A meta-analysis of studies in Italy assessing 5-HTTLPR and AD risk
gave an estimation of odds ratio for the L-allele versus the S-allele of 0.85 (associated P value = .08). Overall, our findings are not
supportive of a large genetic eﬀect of the explored polymorphisms on AD risk.
1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative process
whose prevalence increases with age. The number of AD
patients is expected to raise considerably in the next future
[1]. More than 90% of AD cases are sporadic, and only a little
percentage has a clear genetic cause [2–4]. The main clinical
feature of AD at onset is memory loss, accompanied by
behavioral and psychological symptoms of dementia (BPSD)
encompassing agitation, aggression, sexual disinhibition,
delusions, hallucinations, and sleeping or eating disorders
that are an outstanding managing problem for the caregiver
[5, 6].
Despite the fact that the most important neurochemical
deficiency in AD is related to acetylcholine loss, a possible
role for serotonin (5-HT) in AD was suggested by post-
mortem assays showing reduced level of serotonin in AD
brains [7]. 5-HT role in cognitive processes and memory
has been recently suggested, both in animal models and
in studies on human subjects [8, 9]. Consequently, 5-HT
imbalance might contribute to AD pathological signs. The
5-HT transporter gene (SLC6A4, 17q11.1-q12) codes for
a neuronal transmembrane protein that is devoted to 5-
HT reuptake at presynaptic level, a key regulatory event
for serotonergic transmission [10]. The promoter region
of the SLC6A4 gene bears a functional polymorphism,
2 International Journal of Alzheimer’s Disease
named serotonin-transported linked-polymorphic region
(5-HTTLPR), consisting of a 43-bp insertion or deletion
(ind/del) leading to a hypofunctional short (S) or to a normal
long (L) variant [11, 12]. This polymorphism has been
investigated in association with AD risk (Table 1) [13–19],
and a meta-analysis of the available data shows no significant
eﬀect [20]. A diﬀerent SLC6A4 promoter polymorphism,
rs25531 (A→G), is able to modulate 5-HTTLPR transcrip-
tional eﬃciency, as the presence of the rs25531 G-variant in
an L-allele carrier reduces the normal transcriptional rate
to a level comparable to the S-allele [21]. The genome-
wide association studies performed so far did not report
significant eﬀect for these two genetic variants in relation
to AD susceptibility [22]. In the Italian population, the 5-
HTTLPR has been investigated as risk factor for AD with
conflicting results, while to our knowledge no data are avail-
able for rs25531. To contribute in this field, we have made an
association study in a population from Northern Italy.
2. Materials andMethods
2.1. Patients Recruitment. We recruited 235 independent AD
subjects from two clinical centers: “Luigi Sacco” Hospital
(Milan, Italy) and Ospedale Maggiore Policlinico (Milan,
Italy). Probable AD was diagnosed according to the National
Institute of Neurological and Communicative Disorders and
Stroke criteria (NINCDS-ADRDA). A Hachinski Ischemic
Score >4 was an exclusion criteria [23, 24]. Patients under-
went physical and neurological examination, screening labo-
ratory tests, cognitive evaluation, brain Magnetic Resonance
Imaging (MRI), Computed Tomography (CT), or Positron
Emission Computed Tomography (PET) when required.
Dementia severity was assessed by the Minimental State
Examination (MMSE) [25]. Controls (n = 207) were from
the same clinical centers as above; they were mainly elderly
outpatients coming to clinical attention for non-neurological
illness or spouses of the cases. The absence of cognitive
impairment in controls was measured by MMSE, at baseline
and at least after one-year follow-up. All subjects (or their
relatives) gave an informed consent to the participation in
the study (approved by the local ethical committees) that
followed the principles of the Declaration of Helsinki.
2.2. Blood Samples Collection, 5-HTTLPR, rs25531, and Apoli-
poprotein E Genotyping. About 5mL of blood were collected
by venipuncture, frozen at −20◦C, and extracted to collect
genomic DNA (gDNA) using a commercial kit according to
the manufacturer’s instructions (Promega, Madison, USA).
To assess 5-HTTLPR genotype, 50 ng of gDNA were
amplified by polymerase chain reaction (PCR) with the
following primers: forward: 5
′
-ggcgttgccgctctgaatgc, reverse-
5’-gagggactgagctggacaacca (size of the amplified bands: L-
allele 529 bp; S-allele 486 bp). The rs25531 genotype was
assessed by allele-specific PCR using as primers: forward A-
allele specific: 5
′
-acccctcgcggcatcccccctgcacccaca-3
′
; forward
G-allele specific: 5
′
-acccctcgcggcatcccccctgcacccacg-3
′
; com-
mon reverse: 5
′
-tggagtccgcgcgggattctggtgccacct-3
′
. Finally,
apolipoprotein E (APOE) genotype was assessed as previ-
ously published [26]. To avoid false genotyping, samples
were assessed at least twice and only unambiguous results
were considered.
2.3. Meta-Analysis, Statistical Analysis, and Power Calcula-
tion. The meta-analysis was performed based on association
studies data shown in the public available database http://
www.alzforum.org/ [20]. Calculations were done using the
MetaEasy software v1.0.4 (http://www.jstatsoft.org/v30/i07/
paper). Genotypic or allelic frequencies were compared using
hypothesis-free χ2 test by a free available online resource
[27]. The odds ratios (ORs) were calculated by 2 × 2 con-
tingency table at 95% confidence interval (CI) by GraphPad
Prism 5.0. Power analysis (performed by G∗Power 3.03).
With the sample size of our novel study (a total of 417
subjects), we had 85% power to detect an increase of the S-
allele of 7%, corresponding to a small-to-medium eﬀect size
of w = 0.14 (where w stands for the eﬀect size conventional
index for chi-square test [28]), and a power of 57% to detect
a small eﬀect size of w = 0.10 (an increase of S-allele of 5%).
As for the meta-analysis performed in the Italian population,
the total number of subjects was 1178, and in this case we
had a power of 77% to detect an increase of the S-allele of
5%. The statistical significance limit was set at P = .05.
3. Results
3.1. 5-HTTLPR, rs25531 Genotyping, and APOE-ε4 Stratifica-
tion. AD subjects (n = 235) and controls (CNTR, n = 207)
were screened to assess 5-HTTLPR and rs25531 genotype.
Their demographic data are summarized in Table 2. AD cases
and CNTR were people of Italian ancestry (self-reported,
at least two generations before the patient were born and
resident in Italy), balanced for age and sex proportion.
Genetic results are shown in Table 3. Of the available
235 AD and 207 CNTR, 220 AD (93.6%) and 197 CNTR
(95.2%) were considered for subsequent analysis, with a
genotyping eﬃcacy of 99.5% and an accuracy of 94.8%. We
checked at first Hardy-Weinberg equilibrium and found no
deviation in cases and controls separately for 5-HTTLPR,
while for rs25531 controls had a significant diﬀerence from
the expected genotypic frequencies (χ2=8.29, P = .003),
probably due to a slight overrepresentation of the rare
G/G homozygous genotype in this group. The distribution
of genotypic frequencies of 5-HTTLPR and rs25531 did
not diﬀer between AD and CNTR. However, by assuming
that the presence of at least one S-allele was suﬃcient to
modulate AD risk, we calculated the odds ratio OR (95%
confidence interval (CI)) for the 5-HTTLPR L/L versus
(S/L+S/S) genotype that was 0.62[0.41–0.94], with associated
P-value of P = .02. For rs25531, the comparison considering
(G/A+G/G) genotypes versus A/A genotype gave an OR
(95% (CI)) of 0.83 (0.5–1.5), with associated P value of
P = .59. As for allelic frequencies, the 5-HTTLPR S-allele was
significantly more frequent in AD than CNTR (47.5% versus
40.1%). We have also verified whether the 5-HTTLPR allelic
distribution was independent of the presence of the APOE-ε4
allele (Table 4). The APOE-ε4 allele by itself was a strong risk
factor for AD (OR (95% CI) for carriers versus noncarriers:
5.4 (3.2–8.8), P < .0001). When we divided the 5-HTTLPR
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Table 1: Literature overview of the 5-HTTLPR polymorphism in association with AD in the Caucasian population.
Reference Population
No. of
cases
No. of
controls
Main result
[13] UK 196 271 No association
[14] Germany 84 118 No association
[15] Germany 50 199
Association of S-allele with AD (S-allele
frequency in AD and controls: 51% and
41%, resp.)
[16] Italy 208 116 No association
[17] Italy 105 114 No association
[18] Austria 127 479 No association
[19] Italy 164 54 Association of S-allele with AD
(S-allele frequency in AD and controls: 47%
and 34%, resp.)
This study (no overlapping with
the above-cited populations)
Italy 220 197
Association of S-allele with AD (S-allele
frequency in AD and controls: 47.5% and
40.1%, resp.)
AD: sporadic Alzheimer’s disease.
Table 2: Demographics of the AD sample.
Diagnosis
No. of subjects
(male : female)
Age at sampling
(years ± SD) Age at onset (years ± SD)
Disease duration
(years ± SD)
MMSE score at sampling
(mean ± SD)
AD 235 (74 : 161) 78.6± 9.8 77.2± 8.0 4.1± 1.8 18.7± 5.8
CNTR 207 (69 : 138) 77.0± 9.3 NA NA 28.2± 2.6∗∗
AD: sporadic Alzheimer’s disease;
CNTR: controls;
MMSE: Minimental State Examination;
SD: standard deviation;
NA: not applicable;
∗∗P < .001, Student’s t-test versus AD.
cases and CNTR according to APOE-ε4 status, we did not
find a diﬀerence in the genotypic or allelic distributions.
No variation was found by comparing 5-HTTLPR genotypic
or allelic frequencies between AD APOE-ε4 carriers and
noncarriers.
We also performed a multivariate logistic regression
considering variables: age, sex, rs25531, 5-HTTLPR, and
APOE-ε4 status. The contribution to AD of 5-HTTLPR was
no longer significant (OR: 0.61, 95% CI: 0.38–1.05, P = .10).
As for rs25531, no risk modulation was found (P = .96). We
confirmed the strong influence of APOE-ε4 allele (OR: 6.4,
95% CI: 3.5–11.8, P < .00001).
Finally, we have assessed whether 5-HTTLPR or rs25531
influenced other clinical parameters as age at onset. We
found no association between the 5-HTTLPR or rs25531
genotype and dementia onset (data not shown).
3.2. Meta-Analysis for 5-HTTLPR Studies. Taking advantage
from the public available database http://www.alzforum.org/,
we have performed a meta-analysis of the Italian studies
focused on 5-HTTLPR and risk of AD, including our own
data. We found a marginal eﬀect, with an odds ratio (OR)
and 95% confidence interval (95% CI) of the L-allele versus
the S-allele of 0.85 (0.70–1.03) (Figure 1). We compared
the Italian meta-analysis with a second meta-analysis based
on thirteen studies (regardless of ethnicity) and a third
including eight Caucasian studies only. In the general meta-
analysis the OR (95% CI) was 0.97 (0.87–1.07), while for the
Caucasian meta-analysis the OR (95% CI) was 0.90 (0.79–
1.02) (Figure 1).
4. Discussion
5-HT imbalance might be the biochemical basis of the
etiology of behavioral disturbances that are frequent features
in late-onset AD [29, 30]. However, the genetic variability
linked to the promoter region of the SLC6A4 gene has been
considered as predisposing factor for the development of AD
dementia, too (Table 1). The increased frequency we have
detected in 5-HTTLPR S-allele corresponds to a small-to-
medium eﬀect size (odds ratio (OR) of 1.6), a magnitude
far below the APOE-ε4 allele, but that seems independent
of the presence of this strong risk factor as suggested by
our stratification analysis. However, this observation should
suﬀer from reduced sample size in the groups analyzed, even
though both in ADAPOE-ε4 carriers (+) and ADnoncarriers
(−) the 5-HTTLPR S-allele frequency had a positive trend
in comparison to controls. As for the significance of our
4 International Journal of Alzheimer’s Disease
Table 3: 5-HTTLPR and rs25531 genotypic and allelic frequencies.
Genotype count (%) Allele count (%) OR (95% CI) and P value for allelic
distribution (L-allele versus S-allele)S/S S/L L/L S L
5-HTTLPR
AD (220) 51 (23.2) 107 (48.6) 62 (28.2) 209 (47.5) 231 (52.5)
CNTR (197) 37 (18.8) 84 (42.6) 76 (38.6)∗ 158 (40.1) 236 (59.9) 0.74 (0.56–0.97) and 0.03
Genotype count (%) Allele count (%) OR (95% CI) and P value for allelic
distribution (G-allele versus A-allele)G/G G/A A/A G A
rs25531
AD (220) 0 (0.0) 31 (13.9) 189 (86.1) 31 (7.0) 409 (93.0)
CNTR (197) 5 (2.5) 26 (13.2) 166 (84.3)# 36 (9.1) 358 (90.9) 0.75 (0.45–1.24) and 0.29
AD: sporadic Alzheimer’s disease;
CNTR: controls;
∗= 0.07; # = 0.06∗, P-value calculated from χ2 test for AD versus CNTR as for genotypic distribution;
OR (95% CI): odds ratio and 95% confidence interval calculated from 2× 2 contingency table.
Table 4: Stratification of 5-HTTLPR genotype according to APOE-ε4 status.
Genotype count (%) Allele count (%)
P value
S/S S/L L/L S L
APOE-ε4 (−)
AD (117) 25 (21.6) 57 (48.6) 35 (29.8) 107 (45.7) 127 (54.3) .35a
CNTR (171) 31 (18.1) 75 (43.8) 65 (38.1)a 137 (40.0) 205 (60.0)b .17b
Genotype count (%) Allele count (%)
P value
S/S S/L L/L S L
APOE-ε4 (+)
AD (103) 27 (26.3) 50 (48.5) 26 (25.2) 104 (50.5) 102 (49.5) .57c
CNTR (26) 5 (19.2) 12 (46.1) 9 (34.7)c 22 (42.3) 30 (57.7)d .29d
AD: sporadic Alzheimer’s disease;
CNTR: controls;
P value:P calculated from χ2 test for AD versus CNTR;
a,c genotypic distribution;
b,d allelic distribution.
findings, the association found with unadjusted analysis was
no longer significant after correction by logistic regression
performed considering other variables, such as age, sex, and
APOE-ε4 status, even if the OR coming from the multivariate
regression was similar to the uncorrected analysis, suggesting
that the potential confounders age, sex, and APOE-ε4 do not
strongly influence the association result. A haplotypic study
assessing 5-HTTLPR and rs25531 together might have been
of interest, but our sample was too small to perform this
analysis.
To our knowledge, none of the genome-wide association
studies (GWASs) so far reported in the literature found
an association signal for the SLC6A4 promoter region
and AD, while the case-control studies available to date
addressing the same association are conflicting, even if they
are mostly negative (Table 1). In the Caucasian population
two studies linked 5-HTTLPR and AD, while others did
not reproduce this association (including two studies in the
Italian population, the largest enrolling n = 324 subjects)
[16, 17]. To this respect, our population (n = 417 subjects
with successful genotyping) is a bigger independent sample,
and the indication of an increased frequency of the 5-
HTTLPR S-allele in AD deserves further replication in Italy,
also considering the recent data by Lorenzi et al. reporting
an increased frequency of 5-HTTLPR S-allele in sporadic
demented subjects (AD and frontotemporal lobar dementia
(FTLD)) from the same country [19]. Our data are also in
agreement with the positive association between 5-HTTLPR
and AD from Hu et al. (n = 249 subjects, AD group n =
50) [15], but represent a more accurate replication due to
the increased sample size, in particular for the AD group
(AD group genotyped in our study n = 220). Due to the
Italian population structure and the age of included patients,
we do not envisage a possible bias in our analysis due to
population stratification, even if the Italian ancestry was
self-reported.
The meta-analysis performed by comparing studies with
mixed ethnicity, Caucasian ancestry and Italian ethnicity
have pointed out a marked heterogeneity of results as
demonstrated by the Cochran’s Q-test for heterogeneity
(significant in all the meta-analyses that we made). It is
worth to notice that a trend for an increased risk of
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Li, 1997
Zill, 2000
Kunugi, 2000
Hu, 2000
Tsai, 2001
Ha, 2005
Nishimura, 2005
Forero, 2005
Micheli, 2006
Seripa, 2008
Lorenzi, 2010
This study
All studies I2 = 68.4%
0.16 0.4 1 2.5 6
5-HTTLPR long versus short allele
Gru¨enblatt, 2008
OR (95% CI): 0.97 (0.87–1.07)
Cochrane Q-test P value: .0002;
(a)
Caucasian
Li, 1997
This study
Lorenzi, 2010
Seripa, 2008
Micheli, 2006
Hu, 2000
Zill, 2000
I2 = 79.1%
0.16 0.4 1 2.5 6
5-HTTLPR long versus short allele
Gru¨enblatt, 2008
OR (95% CI): 0.9 (0.79–1.02)
Cochrane Q-test P value: <.00001;
(b)
Italy
This study
Lorenzi, 2010
Seripa, 2008
Micheli, 2006
I2 = 71.4%
0.16 0.4 1 2.5 6
5-HTTLPR long versus short allele
OR (95% CI): 0.85 (0.7–1.03)
Cochrane Q-test P value: .016;
(c)
Figure 1: Meta-analysis of 5-HTTLPR. We have included our own data in three datasets: (a) all nonoverlapping studies regardless of
ethnicity available online (http://www.alzforum.org/ [20]); (b) Caucasian studies only; (c) Italian studies only. The odds ratio (OR) and
95% confidence interval (CI) are calculated for the long (L) versus short (S) allele. The diamond is the output of meta-analysis calculation,
with its OR (95% (CI)).
the S-allele in comparison to the L-allele came to light, with
the Italian population having the highest risk among the
group considered, although not significant. We can speculate
that 5-HTTLPR might be an AD risk factor with a selective
ethnicity eﬀect.
Overall, we acknowledge that the result of our novel
association study is most likely inflated by type-I error,
while the meta-analysis results do not provide nominally
significant evidence for association. However, before a robust
conclusion can be drawn, larger studies would be needed to
definitely assess the role of this marker in AD pathogenesis.
The analysis on rs25531 had first of all the important
limitation of a deviation from Hardy-Weinberg equilibrium
(HWE) in controls. They revealed that rs25531 frequency
in our population considered as a whole was quite limited
(G-allele frequency of 8.0% and homozygous G/G genotype
frequency of 1.2%), so it might explain a small percentage of
AD genetic risk. Moreover, due to the frequency of this SNP
and the departure from HWE in controls, our negative data
should be confirmed in larger datasets. As for a possible link-
age disequilibrium (LD) between rs25531 and 5-HTTLPR we
have already addressed this point with negative results [31].
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